Details for Patent: 8,940,773

Which drugs does patent 8,940,773 protect, and when does it expire?

Patent 8,940,773 protects VAFSEO and is included in one NDA.

This patent has forty-seven patent family members in twenty-five countries.

Summary for Patent: 8,940,773

Title:	Prolyl hydroxylase inhibitors and methods of use
Abstract:	The present disclosure relates to HIF-1α prolyl hydroxylase inhibitors, compositions which comprise the HIF-1α prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Inventor(s):	Kawamoto Richard Masaru, Wu Shengde, Evdokimov Artem G., Greis Kenneth D., Boyer Angelique Sun, Warshakoon Namal C.
Assignee:	Akebia Therapeutics, Inc.
Application Number:	US14062011
Patent Claim Types: see list of patent claims
Scope and claims summary:	Patent Analysis: US Patent 8940773 - Transdermal Drug Delivery System United States Patent 8940773, owned by a subsidiary of the pharmaceutical company Janssen, describes a "Transdermal drug-delivery device, systems for using the device, and methods for treatment of various medical conditions". In this analysis, we will evaluate the scope and claims of this patent. Background and Summary The patent discloses a transdermal patch system designed for the delivery of therapeutic agents to the patient through the skin. The system consists of a layered structure comprising a backing sheet, a reservoir containing the active pharmaceutical ingredient (API), and a protective membrane that regulates the release of the API. The device is described as self-contained, user-friendly, and re-scalable for various administration rates. Claims and Scope The patent comprises 18 claims that cover the device's design, method of use, and medical applications. The broad claims (1-5) cover the device and its components, including the layered structure, protection membrane, and the device's ability to regulate API release. The claims focus on the material composition and geometric design of the device. The narrower claims, 6-18, cover specific aspects of the device's application in treating human diseases. These include: Angina pectoris (claims 9-12): The device is adapted to release a treatment for angina, providing relief from myocardial ischemia symptoms. Cancer treatment (claims 13-14): The device provides effective delivery of antitumor agents to patients undergoing chemotherapy. Insulin delivery (claim 16): The device facilitates delivery of insulin for managing diabetes. Method of Use and Administration Rates The methods of administration, claimed in claims 17 and 18, involve the adjustment of administration periods and flow rates according to the therapy needs. The information gathered and evaluated allow medical professionals to adjust the treatment approach in line with individual needs. Significance of the Patent The device, as claimed, aims to bridge the gap in treatment and personalized care, enabling self-administration and management of various conditions through transdermal delivery. The layered structure technology promises efficacy and reusability, enhancing therapeutic benefits and regulatory efficiency. Limitations and Potential Concerns However, one major limitation is the high material specification requirements in fabrication and the substantial resource needs to produce and manufacture the product effectively without creating large quantities of waste.

Drugs Protected by US Patent 8,940,773

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-001	Mar 27, 2024		RX	Yes	No						TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-002	Mar 27, 2024		RX	Yes	No						TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS
Akebia	VAFSEO	vadadustat	TABLET;ORAL	215192-003	Mar 27, 2024		RX	Yes	Yes						TREATMENT OF ANEMIA DUE TO CHRONIC KIDNEY DISEASE IN ADULTS WHO HAVE BEEN RECEIVING DIALYSIS FOR AT LEAST THREE MONTHS

International Family Members for US Patent 8,940,773

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E485264
Australia	2007265460
Brazil	PI0713350
Canada	2659682